Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Zepbound, Eli Lilly
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nor
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters.
Eli Lilly says Zepbound beat rival weight loss drug Wegovy in head-to-head study
Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, according to Eli Lilly (LLY).
Eli Lilly says its weight loss drug Zepbound outperformed Wegovy in a study
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Eli Lilly’s Zepbound Outperforms Competitor in Weight Loss Trial, Supporting Buy Rating
Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical trial backed by Lilly.
2d
on MSN
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
1d
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
NBC Los Angeles
1mon
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli
Lilly
's blockbuster weight loss drug
Zepbound
and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
1d
Eli Lilly CEO says Mounjaro maker may consider other Wisconsin sites for new plants
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the ...
2d
Eli Lilly’s $3 billion expansion in Kenosha County will mean 750 new jobs
Indianapolis-based Eli Lilly's expansion into Bristol will focus on manufacturing injectable medications, device assembly and ...
2d
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Seeking Alpha on MSN
2d
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
Given the strong demand expected for
Eli
Lilly
's (NYSE:LLY) weight loss treatment
Zepbound
(tirzepatide) in the UK, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback